BTK and B-cell chronic lymphocytic leukemia: Small-molecule inhibitors targeting BCR signaling such as Bruton tyrosine kinase (BTK) inhibitors (e.g., ibrutinib) have become the forefront of CLL therapeutics in the last decade.